Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1745-1750

  Espinel Ingroff, A ^a   Chakrabarti, A ^b   Chowdhary, A ^c   Cordoba, S ^d   Dannaoui, E ^e   Dufresne, P ^f   Fothergill, A ^g   Ghannoum, M ^h   Gonzalez, G M ⁱ   Guarro, J ^j   Kidd, S ^k   Lass Florl C ^l   Meis, J F ^m   Pelaez, T ⁿ   Tortorano, A M ^o   Turnidge, J ^p  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c UNIVERSITY OF DELHI   (India)

^d INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁱ UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^j INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^k SA Pathology   (Australia)

^l INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o UNIVERSITY OF MILAN   (Italy)

^p UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; APOPHYSOMYCES VARIABILIS; ARGENTINA; ARTICLE; AUSTRALIA; BROTH DILUTION; CANADA; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; CUNNINGHAMELLA BERTHOLLETIAE; DRUG DISTRIBUTION; EUROPE; FUNGUS ISOLATION; HUMAN; INDIA; LICHTHEIMIA CORYMBIFERA; MEXICO; MINIMUM INHIBITORY CONCENTRATION; MUCOR; MUCOR CIRCINELLOIDES; MUCOR INDICUS; MUCOR RAMOSISSIMUS; MUCORALES; NONHUMAN; PRIORITY JOURNAL; RHIZOMUCOR PUSILLUS; RHIZOPUS MICROSPORUS; RHIZOPUS ORYZAE; SYNCEPHALASTRUM RACEMOSUM; UNITED STATES; WILD TYPE; CLINICAL TRIAL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MUCORMYCOSIS; MULTICENTER STUDY; MULTIDRUG RESISTANCE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG RESISTANCE, MULTIPLE, FUNGAL; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MUCORALES; MUCORMYCOSIS; TRIAZOLES;

EID: 84923249685     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04435-14     Document Type: Article

References (36)

1. Gomes MZ, Lewis RE, Kontoyiannis DP. 2011. Mucormycosis caused by unusual mucormycetes, non-Rhizopus,-Mucor, and-Lichtheimia species. Clin Microbiol Rev 24:411-445. http://dx.doi.org/10.1128/CMR.00056-10.
2. Kwon-Chung KJ. 2012. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 54:S8-S15. http://dx.doi.org/10.1093/cid/cir864.
3. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikkos G, for the European Confederation of Medical Mycology Working Group on Zygomycosis. 2011. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 17:1859-1867. http://dx.doi.org/10.1111/j.1469-0691.2010.03456.x.
4. Walther G, Pawłowska J, Alastruey-Izquierdo A, Wrzosek M, Rodriguez-Tudela JL, Dolatabadi S, Chakrabarti A, de Hoog GS. 2013. DNA barcoding in Mucorales: an inventory of biodiversity. Persoonia 30:11-47. http://dx.doi.org/10.3767/003158513X665070.
5. Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Freiberger T, Guinea J, Guarro J, de Hoog S, Hope W, Johnson E, Kathuria S, Lackner M, Lass-Florl C, Lortholary O, Meis JF, Meletiadis J, Munoz P, Richardson M, Roilides E, Tortorano AM, Ullmann AJ, van Diepeningen A, Verweij P, Petrikkos G. 2014. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20(Suppl 3):5-26. http://dx.doi.org/10.1111/1469-0691.12371.
6. Ruping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Florl C, Beisel C, Herbrecht CR, Roth Y, Silling G, Ullmann AJ, Borchert K, Egerer G, Maertens J, Maschmeyer G, Simon A, Wattad M, Fischer G, Vehreschild J, Cornely OA. 2010. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 65:296-302. http://dx.doi.org/10.1093/jac/dkp430.
7. Garcia-Hermoso D, Dannaoui E, Lortholary O, Dromer F. 2011. Agents of systemic and subcutaneous mucormycosis and entomophthoromycosis, p 2008-2019. In Versalovic J, et al (ed), Manual of clinical microbiology, 10th ed. ASM Press, Washington, DC.
8. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. 2003. Amphotericin B: time for a new "gold standard." Clin Infect Dis 37:415-425. http://dx.doi.org/10.1086/376634.
9. Pagano L, Caira M, Candoni A, Aversa F, Castagnola C, Caramatti C, Cattaneo C, Delia M, De Paolis MR, Blasi RD, Caprio LD, Fanci R, Garzia M, Martino B, Melillo L, Mitra ME, Nadali G, Nosari A, Picardi M, Potenza L, Salutari P, Trecarichi EM, Tumbarello M, Verga L, Vianelli N, Busca A, SEIFEM Group. 2012. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis 55: 1515-1521. http://dx.doi.org/10.1093/cid/cis773.
10. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42:e61-e65. http://dx.doi.org/10.1086/500212.
11. Vehreschild JJ, Birtel A, Vehreschild MJT, Liss B, Farowski F, Kochanek M, Sieniawski M, Steinbach A, Wahlers K, Fätkenheuer G, Cornely OA. 2013. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 39:310-324. http://dx.doi.org/10.3109/1040841X.2012.711741.
12. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 3rd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Villanova, PA.
13. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MSC, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J. 2014. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 58:2006-2012. http://dx.doi.org/10.1128/AAC.02615-13.
15. Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, Fuller J, Ghannoum M, Johnson E, Pelaez T, Pfaller MA, Turnidge J. 2011. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 55:5150-5154. http://dx.doi.org/10.1128/AAC.00686-11.
16. Espinel-Ingroff A, Cuenca-Estrella M, Cantón E. 2013. EUCAST and CLSI: working together towards a harmonized method for antifungal susceptibility testing. Curr Fungal Infect Rep 7:59-67. http://dx.doi.org/10.1007/s12281-012-0125-7.
17. Turnidge J, Kahmeter G, Kronvall G. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418-425. http://dx.doi.org/10.1111/j.1469-0691.2006.01377.x.
18. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. 2008. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 46:567-573. http://dx.doi.org/10.1080/1369378080 1975576.
19. Alastruey-Izquierdo A, Castelli MV, Cuesta I, Monzon A, Cuenca-Estrella M, Rodriguez-Tudela J-L. 2009. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob Agents Chemother 53:1686-1689. http://dx.doi.org/10.1128/AAC.01467-08.
20. Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, Baghela A, Klaassen CH, Meis JF. 2010. Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern. J Clin Microbiol 48:4580-4585. http://dx.doi.org/10.1128/JCM.01420-10.
21. Vitale RG, Sybren de Hoog G, Schwarz P, Dannaoui E, Deng S, Machouart Marie Voigt K, van de Sande WWJ, Dolatabadi S, Meis JF, Walther G. 2012. Antifungal susceptibility and phylogeny of opportunistic members of the order Mucorales. J Clin Microbiol 50:66-75. http://dx.doi.org/10.1128/JCM.06133-11.
22. Alastruey-Izquierdo A, Castelli MV, Cuesta I, Zaragoza O, Monzon A, Mellado E, Rodriguez-Tudela JL. 2009. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 15:71-76. http://dx.doi.org/10.1111/j.1469-0691.2009.02984.x.
23. Halliday CL, Kidd SE, Sorrell TC, Chen SC-A. Molecular diagnostic methods for invasive fungal disease: the horizon draws nearer. Pathology, in press.
24. Turnidge J, Bordash G. 2007. Statistical methods for establishing quality control limits in Clinical and Laboratory Standards Institute susceptibility testing. Antimicrob Agents Chemother 51:2483-2488. http://dx.doi.org/10.1128/AAC.01457-06.
25. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20:391-408. http://dx.doi.org/10.1128/CMR.00047-06.
26. Dalhoff A, Ambrose PG, Mouton JW. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37: 296-305. http://dx.doi.org/10.1007/s15010-009-7108-9.
27. Salas V, Pastor FJ, Calvo E, Sutton DA, Chander J, Mayayo E, Alvarez E, Guarro J. 2012. Efficacy of posaconazole in a murine model of disseminated infection caused by Apophysomyces variabilis. J Antimicrob Chemother 67:1712-1715. http://dx.doi.org/10.1093/jac/dks090.
28. Araujo R, Espinel-Ingroff A. 2010. Antifungal resistance: cellular and molecular mechanisms. In Ahmad I, et al (ed). Combating fungal infections: problems and remedy. Springer, London, United Kingdom.
29. Blum G, Hörtnagl C, Jukic E, Erbeznik T, Pümpel T, Dietrich H, Nagl M, Speth C, Rambach G, Lass-Flörl C. 2013. New insight into amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother 57:1583-1588. http://dx.doi.org/10.1128/AAC.01283-12.
30. Lestner JM, Howard SJ, Goodwin J, Gregson L, Majithiya J, Walsh TJ, Jensen GM, Hope WW. 2010. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericinB lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 54:3432-3441. http://dx.doi.org/10.1128/AAC.01586-09.
31. Petrikkos G, Skiada A, Drogari-Apiranthitou M. 2014. Epidemiology of mucormycosis in Europe. Clin Microbiol Infect 20:67-73. http://dx.doi.org/10.1111/1469-0691.12563.
32. Rodríguez MM, Pastor JF, Sutton DA, Calvo E, Fothergill AW, Salas V, Rinaldi MG, Guarro J. 2010. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother 54:1665-1669. http://dx.doi.org/10.1128/AAC.01463-09.
33. Rodríguez MM, F. Pastor JF, Calvo E, Salas V, Sutton DA, Guarro J. 2009. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother 53:5022-5025. http://dx.doi.org/10.1128/AAC.01026-09.
34. Spreghini E, Orlando F, Giannini D, Barchiesi F. 2010. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. J Antimicrob Chemother 65:2158-2163. http://dx.doi.org/10.1093/jac/dkq276.
35. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. 2002. In vivo activity of posaconazole against Mucor spp. in an Immunosuppressed-mouse model. Antimicrob Agents Chemother 46:2310-2312. http://dx.doi.org/10.1128/AAC.46.7.2310-2312.2002.
36. Salas V, Pastor FJ, Calvo E, Alvarez E, Sutton DA, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J. 2012. In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole. Antimicrob Agents Chemother 56:2246-2250. http://dx.doi.org/10.1128/AAC.05956-11.